TD Cowen downgraded Illumina to Market Perform from Outperform with an unchanged price target of $144. The analyst cites valuation for the downgrade. The shares are up 40% from the recent lows and are now within 10% of the price target, the analyst tells investors in a research note. The firm sees a more balanced risk/reward at current share levels, saying revenue forecasts reflect a “realistic outcome” for Illumina “given the opportunities and challenges that persist.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ILMN:
- SHAREHOLDER ALERT: Potential Recovery for Illumina, Inc. (ILMN) Investors
- SomaLogic sent letter to stockholders on transaction with Standard BioTools
- Early notable gainers among liquid option names on December 20th
- Amgen upgraded, PepsiCo downgraded: Wall Street’s top analyst calls
- Illumina price target lowered to $258 from $260 at RBC Capital